Breast cancer adherence study aims to uncover why patients stop taking Life-Saving pills
NCT ID NCT06650423
First seen Mar 28, 2026 · Last updated Jun 20, 2026 · Updated 14 times
Summary
This study tracks 319 women with early-stage, hormone receptor-positive, HER2-negative breast cancer to see how well they take their prescribed aromatase inhibitors, with or without the added drug abemaciclib. Researchers will measure adherence using pill counts and questionnaires at 3 and 6 months. The goal is to identify factors like quality of life, cognitive function, and attitudes toward therapy that influence whether patients stick with their treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2 NEGATIVE BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Oncology Ljubljana
RECRUITINGLjubljana, 1000, Slovenia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
aromatase inhibitors (letrozole, anastrozole, or exemestane) with or without abemaciclib
What this could lead to
If this study succeeds, it could help doctors understand why some patients stop taking their medication and find ways to improve adherence, potentially reducing cancer recurrence.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly test a new therapy. Results may not apply to patients outside Slovenia or those on different treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.